Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
46.67
-0.75 (-1.58%)
At close: Dec 5, 2025, 4:00 PM EST
46.60
-0.07 (-0.15%)
After-hours: Dec 5, 2025, 5:48 PM EST
Crinetics Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 1.54 | 1.04 | 4.01 | 4.74 | 1.08 | 0.07 | |
| Revenue Growth (YoY) | 47.74% | -74.11% | -15.28% | 339.43% | 1418.31% | -94.05% | |
| Cost of Revenue | 313.57 | 240.16 | 168.53 | 130.23 | 84.26 | 57 | |
| Gross Profit | -312.04 | -239.12 | -164.51 | -125.49 | -83.18 | -56.93 | |
| Selling, General & Admin | 165.81 | 99.74 | 58.09 | 42.39 | 24.53 | 18.03 | |
| Operating Expenses | 165.81 | 99.74 | 58.09 | 42.39 | 24.53 | 18.03 | |
| Operating Income | -477.85 | -338.85 | -222.61 | -167.88 | -107.7 | -74.95 | |
| Interest & Investment Income | 55.2 | 41.44 | 13.44 | 4.32 | 0.16 | 0.99 | |
| Earnings From Equity Investments | - | -0.47 | -5.2 | -1.01 | - | - | |
| Currency Exchange Gain (Loss) | - | - | - | - | -0.11 | - | |
| Other Non Operating Income (Expenses) | -0.45 | -0.52 | -0.16 | 0.66 | 0.01 | 0.15 | |
| Pretax Income | -423.1 | -298.41 | -214.53 | -163.92 | -107.64 | -73.81 | |
| Net Income | -423.1 | -298.41 | -214.53 | -163.92 | -107.64 | -73.81 | |
| Net Income to Common | -423.1 | -298.41 | -214.53 | -163.92 | -107.64 | -73.81 | |
| Shares Outstanding (Basic) | 93 | 81 | 58 | 52 | 38 | 30 | |
| Shares Outstanding (Diluted) | 93 | 81 | 58 | 52 | 38 | 30 | |
| Shares Change (YoY) | 24.75% | 39.11% | 11.71% | 35.24% | 26.24% | 25.95% | |
| EPS (Basic) | -4.54 | -3.69 | -3.69 | -3.15 | -2.80 | -2.42 | |
| EPS (Diluted) | -4.54 | -3.69 | -3.69 | -3.15 | -2.80 | -2.42 | |
| Free Cash Flow | -354 | -229.81 | -171 | -116.86 | -89.02 | -62.21 | |
| Free Cash Flow Per Share | -3.80 | -2.85 | -2.94 | -2.25 | -2.32 | -2.04 | |
| Operating Margin | -31130.16% | -32613.47% | -5547.17% | -3544.06% | -9990.91% | -105567.61% | |
| Profit Margin | -27563.32% | -28720.69% | -5345.85% | -3460.38% | -9985.25% | -103960.56% | |
| Free Cash Flow Margin | -23061.95% | -22118.77% | -4261.03% | -2466.98% | -8258.26% | -87623.94% | |
| EBITDA | -474.16 | -336.07 | -221.51 | -166.9 | -106.78 | -74.01 | |
| D&A For EBITDA | 3.68 | 2.79 | 1.1 | 0.98 | 0.92 | 0.95 | |
| EBIT | -477.85 | -338.85 | -222.61 | -167.88 | -107.7 | -74.95 | |
| Revenue as Reported | - | - | - | - | - | 0.07 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.